Pfizer Inc. (NYSE:PFE) ranks among the best set-it-and-forget-it stocks to buy. On June 26, Pfizer Inc. (NYSE:PFE) declared ...

On June 26, Pfizer announced positive topline results from its Phase 3 BASIS study evaluating HYMPAVZI (marstacimab) for ...

Pfizer's Hympavzi meets key phase III goals, demonstrating a significant reduction in bleeding in hemophilia patients with ...

Discover why options trading trends, robust R&D, and strong free cash flow position Pfizer Inc. for growth. Click for my ...

Pfizer’s Hympavzi, given as a once-weekly subcutaneous injection using a pre-filled pen, works by reducing the amount of TFPI ...

Pfizer PFE announced that the phase III BASIS study evaluating its anti-TFPI inhibitor Hympavzi (marstacimab) for treating patients with hemophilia A or B with inhibitors met its primary endpoint ...

Recent health news highlights include a UK hospital-related death due to a cyberattack, Walgreens beating profit estimates ...

Pfizer's Hympavzi has become the first once-weekly subcutaneous treatment for people living with severe haemophilia B in the EU that can be delivered via an autoinjector device at home. The once ...

Hympavzi has been given a list price of $795,600 per year before discounts and rebates, which Pfizer said was in line with other prophylactic treatments for haemophilia A or B currently available ...